Skip to main content
. 2021 Sep 28;12(20):2006–2021. doi: 10.18632/oncotarget.28075

Figure 2. Creation of pan-drug, drug-specific, drug class-specific, p53-independent, and p53-dependent gene signatures.

Figure 2

(A) Experimental design used to create gene signatures. HCT116 and HCT116 p53−/− cells were treated with cisplatin, oxaliplatin, CPT-11, or 5-FU at their IC50 for 8 hours and RNA expression relative to an untreated control was measured using microarrays. (B) The master gene list was divided into pan-drug, drug-specific, drug class-specific, p53-independent, and p53-dependent gene signatures. (C) Filtering method used to create p53-independent and -dependent gene signatures.